NCT01668966View on ClinicalTrials.gov

A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 9, 2013

Primary Completion Date

May 11, 2016

Study Completion Date

May 11, 2016

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Tocilizumab

Participants will receive tocilizumab 8 mg/kg IV every 4 weeks for up to 104 weeks.

Trial Locations (6)

74110-120

CIP - Centro Internacional de Pesquisa, Goiânia

36036-330

Centro Mineiro de Pesquisa - CMIP, Juiz de Fora

80030-110

Centro de Estudos em Terapias Inovadoras - CETI, Curtiba

90610-000

Hospital Sao Lucas - PUCRS, Porto Alegre

04026-000

Universidade Federal de Sao Paulo - UNIFESP; Reumatologia, São Paulo

04266-010

Centro Paulista de Investigacao Clinica - CEPIC, São Paulo

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01668966 - A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA) | Biotech Hunter | Biotech Hunter